Search results for "Drug Eruptions"

showing 10 items of 17 documents

Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microa…

2016

Purpose: Erlotinib is a targeted agent commonly used in advanced non-small cell lung cancer (aNSCLC). However, drug-related skin toxicity often may affect the quality of life of cancer patients and lead to treatment discontinuation. Genetic polymorphisms in drug transporters and metabolizing enzymes play a major role in the interindividual variability in terms of efficacy and toxicity of erlotinib treatment. The aim of our study was to identify genetic determinants in adsorption, distribution, metabolism, and excretion genes influencing skin rash (SR) by the novel drug-metabolizing enzyme and transporter (DMET) microarray Affymetrix platform in aNSCLC patients. Methods: In a retrospective s…

0301 basic medicineOncologyMaleCancer ResearchLung Neoplasmsgenetic structuresMicroarrayPharmacologyToxicologySkin rash.0302 clinical medicineNon-small cell lung cancerCarcinoma Non-Small-Cell LungGenotypePharmacology (medical)Erlotinib HydrochlorideCholecalciferolOligonucleotide Array Sequence AnalysisSkin rashMiddle AgedOncologyErlotinib030220 oncology & carcinogenesisFemaleErlotinibDrug Eruptionsmedicine.drugmedicine.medical_specialtyGenotypeSingle-nucleotide polymorphismAntineoplastic AgentsPolymorphism Single Nucleotide03 medical and health sciencesErlotinib HydrochlorideInternal medicinemedicineHumansLung cancerAgedRetrospective StudiesPharmacology25-Hydroxyvitamin D3 1-alpha-HydroxylaseInflammationbusiness.industryMicroarray analysis techniquesCancerSingle nucleotide polymorphismsmedicine.diseaseSingle nucleotide polymorphism030104 developmental biologyDMETQuality of Lifebusiness
researchProduct

Monocyte-derived inflammatory Langerhans cells and dermal dendritic cells mediate psoriasis-like inflammation

2016

Dendritic cells (DCs) have been implicated in the pathogenesis of psoriasis but the roles for specific DC subsets are not well defined. Here we show that DCs are required for psoriasis-like changes in mouse skin induced by the local injection of IL-23. However, Flt3L-dependent DCs and resident Langerhans cells are dispensable for the inflammation. In epidermis and dermis, the critical DCs are TNF-producing and IL-1β-producing monocyte-derived DCs, including a population of inflammatory Langerhans cells. Depleting Ly6Chi blood monocytes reduces DC accumulation and the skin changes induced either by injecting IL-23 or by application of the TLR7 agonist imiquimod. Moreover, we find that IL-23-…

0301 basic medicineSciencePopulationGeneral Physics and Astronomychemical and pharmacologic phenomenaInflammationInterleukin-23ArticleMonocytesGeneral Biochemistry Genetics and Molecular BiologyProinflammatory cytokineMajor Histocompatibility ComplexMice03 medical and health sciencesAdjuvants ImmunologicPsoriasismedicineInterleukin 23AnimalsHumansPsoriasiseducationSkinInflammationMice Knockouteducation.field_of_studyImiquimodMultidisciplinaryFollicular dendritic cellsbusiness.industryMonocyteQMembrane Proteinshemic and immune systemsDendritic CellsGeneral ChemistryTLR7medicine.disease3. Good health030104 developmental biologymedicine.anatomical_structureGene Expression RegulationLangerhans CellsImmunologyAminoquinolinesDrug Eruptionsmedicine.symptombusinessNature Communications
researchProduct

Gender differences in adverse drug reactions in dermatological patients in west Sicily: an epidemiological study

2013

Purpose: The purpose of this study was to show that gender also plays an important role in pharmacokinetics, pharmacodynamics, and drug toxicity. It is only fair to take into account the so-called “gender-based medicine.” Methods: We again selected admission for cutaneous adverse drug reaction (CADRs), from January 2012 to July 2012, in order to detect and verify, in an analytical way, the substantial gender differences in adverse drug reactions in term incidence, clinical manifestations, severity and drugs involved. Results:In the period January–July 2012, at the Department of Dermatology and Sexually Transmitted Disease of A.O.U.P. “Paolo Giaccone” Palermo, 384 patients were admitted, of …

AdultMaleSexually transmitted diseasemedicine.medical_specialtyDermatologyPharmacologySex FactorsPharmacokineticsInternal medicineEpidemiologyPharmacovigilancemedicineSettore MED/35 - Malattie Cutanee E VenereeHumansSicilyRetrospective Studiesbusiness.industryIncidenceIncidence (epidemiology)Retrospective cohort studyadverse drug reactions gender-based medicine pharmacovigilanceMiddle Agedmedicine.diseasePharmacodynamicsFemaleDrug EruptionsbusinessAdverse drug reaction
researchProduct

Retrospective analysis of fixed drug eruptions among patients attending a tertiary care center in Southern India

2014

AdultMalemedicine.medical_specialtyAdolescentIndiaDermatologyTertiary careTertiary Care CentersYoung Adultlcsh:DermatologyRetrospective analysisHumansMedicineCenter (algebra and category theory)Fixed drug eruptionsAgedRetrospective Studiesbusiness.industryAnti-Inflammatory Agents Non-SteroidalMiddle Agedlcsh:RL1-803medicine.diseaseAnti-Bacterial AgentsInfectious DiseasesEmergency medicineFemaleDrug EruptionsMedical emergencybusinessIndian Journal of Dermatology, Venereology, and Leprology
researchProduct

[Correlation, in previously treated HIV-1 positive patients, between hypersensitivity reaction to abacavir and the presence of the HLA-B*5701 allele].

2009

Abstract Introduction Hypersensitivity reaction to abacavir (a powerful inverse transcriptase inhibitor) is a serious adverse effect that limits its use in antiretroviral treatment and requires a high level of clinical surveillance. Certain haplotypes of the primary histocompatibility complex proteins (HLA-B*5701) are very significant predictors of the risk of hypersensitivity to this drug. The purpose of this study is to identify the cases where a probable hypersensitivity reaction to abacavir presented the HLA-B*5701 allele. Method A retrospective study was conducted in all HIV-1 positive adult patients infected treated with abacavir between January 2000 and December 2007, in Department 6…

AdultMalemedicine.medical_specialtyFeverGenotypeAnti-HIV AgentsGastrointestinal DiseasesGenes MHC Class IHIV InfectionsPharmacotherapyAbacavirInternal medicineGenotypemedicineHumansGenetic Predisposition to DiseaseAdverse effectAgedRetrospective Studiesbusiness.industryRetrospective cohort studyMiddle AgedRashDideoxynucleosidesHypersensitivity reactionHLA-B AntigensImmunologyHIV-1Reverse Transcriptase InhibitorsFemaleDrug Eruptionsmedicine.symptombusinessPharmacogeneticsmedicine.drugFarmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria
researchProduct

Pitfall prayer marks: Recognition and appropriate treatment: A case report and review of literature.

2019

Prayer marks are asymptomatic callosities resulting from repeated, extended pressure, and friction exerted on bony prominences when praying on hard ground. A 41-year-old woman with ulcerative colitis treated with infliximab was referred to our clinic due to skin changes on her feet that were suspected to be drug eruptions. The patient presented several asymptomatic, hyperpigmented, and hyperkeratotic plaques over the lateral malleoli suggesting that the lesions had a mechanical cause. Further exploration revealed that the patient, a practicing Muslim, prays in a sitting position called "Julus" several times a day. After color marking, the lesions over the lateral feet left a precise imprint…

Adultmedicine.medical_specialtymedia_common.quotation_subjectDermatologyIslam030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineHyperpigmentationMedicineHumansmedia_commonSkinCallositybusiness.industryFootGeneral surgeryGeneral MedicinehumanitiesPrayerInfliximab030220 oncology & carcinogenesisColitis UlcerativeFemaleHyperkeratotic plaquesDrug EruptionsbusinessSkin lesionDermatologic therapyREFERENCES
researchProduct

Interleukin-2 immediate type hypersensitivity?

2008

Two patients with metastatic malignant melanoma developed immediate type hypersensitivity-like symptoms while being treated with recombinant interleukin-(IL-)2 immunotherapy. Both patients showed positive skin prick tests to IL-2, enhanced basophil degranulation in vitro and responded to anti-histamines, but laboratory investigations suggested an IgE-independent, pseudoallergic mast cell degranulation against IL-2.

Interleukin 2AdultMalemedicine.medical_treatmentDermatologyImmunoglobulin EBasophil degranulationlaw.inventionlawmedicineHumansbiologybusiness.industryDegranulationImmunotherapyMiddle Agedmedicine.diseaseIn vitroImmunologybiology.proteinRecombinant DNAInterleukin-2FemaleDrug Eruptionsbusinessmedicine.drugType I hypersensitivityJournal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
researchProduct

A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treat…

2017

Abstract Lessons Learned Cobimetinib and duligotuzumab were well tolerated as single agents and in combination with other agents. The cobimetinib and duligotuzumab combination was associated with increased toxicity, most notably gastrointestinal, and limited efficacy in the patient population tested. Background KRAS-mutant tumors possess abnormal mitogen-activated protein kinases (MAPK) pathway signaling, leading to dysregulated cell proliferation. Cobimetinib blocks MAPK signaling. The dual-action antibody duligotuzumab (MEHD7945A) inhibits ligand binding to both epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3). Blockade of EGFR/HER3 and inhibitio…

Male0301 basic medicineOncologyMAPK/ERK pathwayCancer ResearchReceptor ErbB-3MAP Kinase Kinase 1Administration Oralmedicine.disease_causechemistry.chemical_compound0302 clinical medicinePiperidinesAntineoplastic Combined Chemotherapy ProtocolsMedicineProspective StudiesEpidermal growth factor receptor31biologyMiddle AgedErbB ReceptorsTreatment OutcomeOncologyTolerability030220 oncology & carcinogenesisFemaleDrug EruptionsKRASmedicine.symptomColorectal NeoplasmsSignal TransductionAdultmedicine.medical_specialty4HypokalemiaAcneiform eruptionProto-Oncogene Proteins p21(ras)03 medical and health sciencesAcneiform EruptionsInternal medicineHumansAdverse effectAgedNeoplasm StagingCobimetinibDose-Response Relationship Drugbusiness.industryClinical Trial Resultsmedicine.disease030104 developmental biologychemistryAstheniaImmunoglobulin Gbiology.proteinAzetidinesbusinessProgressive diseaseThe Oncologist
researchProduct

Physician–patient communication and patient-reported outcomes in the actinic keratosis treatment adherence initiative (AK-TRAIN): a multicenter, pros…

2017

Background: Patients with multiple actinic keratoses (AKs) should be treated with field-directed therapy. Such treatments challenge patients’ adherence due to out-of-pocket costs, length of treatment and severity of local skin reactions (LSRs). Effective physician–patient communication (PPC) may buffer therapy-related distress, thus improving quality of life, treatment satisfaction and adherence. Objectives: We evaluated the interplay between PPC, LSR intensity (safety) and lesion clearance rates (effectiveness) on treatment satisfaction, quality of life and treatment adherence among patients with multiple AKs receiving topical field-directed therapies. Methods: In this observational, multi…

Male2708; infectious diseases; actinic keratosesDiclofenacActinictopical field‐directed therapyAnti-Inflammatory AgentsAntineoplastic AgentsAdministration CutaneousMedication AdherenceAdministration Cutaneous; Aged; Aged 80 and over; Anti-Inflammatory Agents Non-Steroidal; Antineoplastic Agents; Diclofenac; Diterpenes; Drug Eruptions; Female; Humans; Imiquimod; Italy; Keratosis Actinic; Longitudinal Studies; Male; Middle Aged; Patient Reported Outcome Measures; Prospective Studies; Quality of Life; Communication; Medication Adherence; Patient Satisfaction; Physician-Patient Relationsactinic keratoses2708; Infectious Diseases80 and overHumansLongitudinal StudiesPatient Reported Outcome MeasuresProspective Studiesactinic keratoseAgedAged 80 and overPhysician-Patient RelationsImiquimodtreatmentCommunicationAnti-Inflammatory Agents Non-SteroidalKeratosisMiddle AgedKeratosis ActinicInfectious DiseasesCutaneousItalyPatient SatisfactionAdministrationQuality of LifeFemaleDrug EruptionsDiterpenesSettore MED/35 - MALATTIE CUTANEE E VENEREENon-Steroidal2708
researchProduct

Early Skin Toxicity as a Predictive Factor for Tumor Control in Hepatocellular Carcinoma Patients Treated with Sorafenib.

2010

Abstract Introduction. Sorafenib is an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases and has led to a longer median overall survival (OS) time and time to progression (TTP) in patients with advanced hepatocellular carcinoma (HCC). This study was conducted to assess the link between the antitumor efficacy of sorafenib and its early cutaneous side effects in advanced HCC patients. Materials and Methods. All patients received 800 mg daily of sorafenib until progression or unacceptable toxicities. We retrospectively analyzed the incidence of rash and hand–foot skin reactions (HFSR) during the first month of treatment, comparing tumor control (partial response …

MaleCancer ResearchPyridinesSettore MED/06 - Oncologia MedicaKaplan-Meier EstimateGastroenterologySkin Toxicity Hepatocellular CarcinomaSorafenib.Aged 80 and overintegumentary systemIncidence (epidemiology)BenzenesulfonatesLiver NeoplasmsMiddle AgedSorafenibRashhumanitiesOncologyHepatocellular carcinomaToxicityDisease ProgressionFemaleDrug Eruptionsmedicine.symptommedicine.drugAdultNiacinamideSorafenibmedicine.medical_specialtyCarcinoma HepatocellularAntineoplastic AgentsInternal medicinemedicineCarcinomaHumansneoplasmsSurvival analysisAgedRetrospective StudiesSurrogate endpointbusiness.industryPhenylurea CompoundsExanthemamedicine.diseaseSurvival Analysisdigestive system diseasesSurgerybody regionsMultivariate AnalysisHepatobiliarybusiness
researchProduct